ClinicalTrials.gg
RecruitingNCT06366828MODELSUpdated Apr 16, 2024

Prediction Models for Complications After CRT in Esophageal Cancer

An observational study in The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection), sponsored by University Medical Center Groningen. Recruiting at 8 sites in Netherlands. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by University Medical Center Groningen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Esophageal Neoplasms by University Medical Center Groningen — 8 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · University Medical Center Groningen.

Started
2023
with 1 other
Observational
7 of 16
5 open now
Registered
14th of 16
by date

Among the 16 studies in Esophageal Neoplasms by University Medical Center Groningen, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 14th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

8 of the 16 studies in Esophageal Neoplasms by University Medical Center Groningen are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Esophageal Neoplasms by University Medical Center Groningen, or all of them as a file.
02

Study summary

The aim of this project is to develop and validate NTCP-models for complications after nCRT (and surgical resection), that can be uses for model-based dose optimization for PhRT and PRT, and for model-based selection for PRT, in patients with esophageal cancer

Read the detailed description

Plan of investigation

In the present project we aim to evaluate two potential strategies to predict and consider a broad spectrum of complications for radiotherapy plan optimization and patient selection:

A comprehensive set of separate NTCP-models for several cardiopulmonary and post-operative complications after nCRT, which results in an NTCP-profile.

A single multivariable NTCP-model for a so-called Complication Sum Score (CSS), which is a single composite complication endpoint including all complications after nCRT, weighted depending on severity and impact.

These prediction models can be used for RT plan optimization and patient selection.

In order to develop these prediction models the project consortium brings together existing prospective data registries for esophageal cancer, namely the Dutch Upper GI Cancer Audit (DUCA) and the Dutch Cancer Registry (NKR) (as well as the POCOP study).

The data of these registries will be linked to a retrospective radiotherapy database using the ProTRAIT infrastructure, resulting in a dataset of over 2000 patients.

In this retrospective cohort study, we will focus on esophageal cancer patients who were treated with nCRT, and for whom an esophagectomy was intended. We will include the patients who received nCRT and the esophagectomy in one of the participating centers. Patients who only received nCRT in one of the participating centers and for whom surgical resection was omitted will be included as well. Detailed eligibility criteria can be found in that section.

Eligible patients will be identified by the Dutch Cancer Registry. The surviving patients will be asked to provide informed consent for participation in this study, permission to combine the different data registries and for future use of their data. Patients who died will be included as well, unless they objected agains the use of there data in the participating centers.

Of the participating patients, the radiotherapy plan-CT and treatment plans (i.e. RTplan, RT struct, RT dose), will be pseudo-anonymized, uploaded and transferred to the UMCG data platform, by the participating radiotherapy centers.

A third trusted party, Zorg TTP, will be responsible for the pseudonymization of the three data sources; the Dutch upper GI cancer audit (DUCA), the Dutch Cancer Registry (NKR) and the RTregistry. After that the linkage will be performed at the UMCG.

03

Conditions studied

  • The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection)

Keywords

  • prediction models
  • esophageal cancer (EC)
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with esophageal cancer, treated with nCRT between 2015-2021 in the participating centers. See eligibility criteria above.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tumor in the esophagus, proven or suspect for esophageal carcinoma
  • WHO performance 0-2
  • Age>18years
  • No distant (M0)
  • Treated with nCRT and planned for or followed by an esophagectomy between 2015 and 2021 in one of the participating centers.

Exclusion criteria

Exclusion Criteria:

  • Sarcoma, neuro-endocrine or small cell carcinoma of the esophagus
  • Patients who underwent a surgical resection in a non-participating surgical center will be excluded
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Interventions

  • Otherretrospective

    follow up

06

What researchers measure

Primary outcomes

  1. Multivariable NTCP models will be developed for the prediction of the following

    Postoperative complications (graded by ECCG classification (3) ): Atrial fibrillation ≥grade 2 Pneumonia ≥grade 2 Respiratory failure requiring re-intubation Anastomotic leakage ≥ grade 2

    Time frame: Within 90 days after surgery

  2. Cardiac events grade II or higher (CTCAE v 5.0), including:

    Pericardial effusion Myocardial infarction and other acute coronary events Heart failure Pericardial effusion Myocardial infarction and other acute coronary events Heart failure Atrial fibrillation

    Time frame: 1 and 2 year after nCRT

  3. Mortality

    Mortality

    Time frame: 1 and 2 year after nCRT

  4. Complication Sum Score, that will be determined in Delphi consensus

    Complication Sum Score, that will be determined in Delphi consensus

    Time frame: 1 year after nCRT

Secondary outcomes

  1. Patient-rated dysphagia

    Patient-rated dysphagia

    Time frame: Up to 30 days after nCRT

  2. Patient-rated nausea

    Patient-rated nausea

    Time frame: Up to 30 day after nCRT

  3. Patient-rated fatigue / daily functioning

    Patient-rated fatigue / daily functioning

    Time frame: Up to 6 months after nCRT

  4. Hospitalization after esophagectomy (days)

    Hospitalization after esophagectomy (days)

    Time frame: Hospitalization after esophagectomy, average 12 days

  5. Intensive care unit stay after esophagectomy (days)

    Intensive care unit stay after esophagectomy (days)

    Time frame: Intensive care unit stay after esophagectomy, average 1.5 days

07

Study locations

7 of 8 sites recruiting
  • Radboud UMC
    Nijmegen, Gelderland 6525GA, Netherlands
    Recruiting
    • H. Rutten, MD · Contact
  • Maastro clinic
    Maastricht, Limburg 6229ET, Netherlands
    Recruiting
    • M. Berbee, MD, PHD · Contact
  • Amsterdam UMC
    Amsterdam, Noord-Holland 1105AZ, Netherlands
    Recruiting
    • P. van Rossum, MD, PHD · Contact
    • H.W.M. van Laarhoven, MD, PHD · Principal investigator
  • Erasmus MC
    Rotterdam, Zuid-Holland 3015GE, Netherlands
    Recruiting
    • J. Nuyttens, MD, PHD · Contact
    • B. Wijnhoven, MD, PHD · Principal investigator
  • Holland PTC
    Delft, Netherlands
    Not yet recruiting
    • Yvonne Klaver, MD, PHD · Contact
  • UMCG
    Groningen, 9715GZ, Netherlands
    Recruiting
    • Christina Muijs, MD, PHD · Contactc.t.muijs@umcg.nl · 0503616161
    • C. T. Muijs, MD, PHD · Principal investigator
    • J. A. Langendijk, Prof., MD, PHD · Sub investigator
    • B. van Etten, MD, PHD · Sub investigator
    • J. J. de Haan, MD, PHD · Sub investigator
  • Zuyderland hospital
    Heerlen, Netherlands
    Recruiting
    • Meindert Sosef, MD · Contact
  • UMCU
    Utrecht, 3584CX, Netherlands
    Recruiting
    • G Meijer, PHD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Jun 2025, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Apr 16, 2024
StartActual
Feb 1, 2023
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2030
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06366828
Collaborators
Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Dutch Institute for Clinical Auditing (DICA), ZorgTTP
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Feb 1, 2023
Primary completion
Jun 2025 (estimated)
Completion
Jun 2030 (estimated)
Last update
Apr 16, 2024

Study contacts

Christina Muijs, Dr.
Contact
c.t.muijs@umcg.nl
0503616161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion